Searched for:
(1 - 20 of 39)

Pages

document
Hoeke, G. (author), Wang, Y. (author), van Dam, A.D. (author), Mol, M. (author), Gart, E. (author), Klop, H.G. (author), van den Berg, S.M. (author), Pieterman, E.H. (author), Princen, H.M.G. (author), Groen, A.K. (author), Rensen, P.C.N. (author), Berbée, J.F.P. (author), Boon, M.R. (author)
Background and aims Activation of brown adipose tissue (BAT) reduces both hyperlipidemia and atherosclerosis by increasing the uptake of triglyceride-derived fatty acids by BAT, accompanied by formation and clearance of lipoprotein remnants. We tested the hypothesis that the hepatic uptake of lipoprotein remnants generated by BAT activation...
article 2017
document
Kühnast, S. (author), van der Tuin, S.J.L. (author), van der Hoorn, J.W.A. (author), van Klinken, J.B. (author), Simic, B. (author), Pieterman, E. (author), Havekes, L.M. (author), Landmesser, U. (author), Lüscher, T.F. (author), van Dijk, K.W. (author), Rensen, P.C.N. (author), Jukema, J.W. (author), Princen, H.M.G. (author)
Background The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from atheroprotective HDL to...
article 2015
document
Kooijman, S. (author), Meurs, I. (author), van der Stoep, M. (author), Habets, K.L. (author), Lammers, B. (author), Berbée, J.F.P. (author), Havekes, L.M. (author), van Eck, M. (author), Romijn, J.A. (author), Korporaal, S.J.A. (author), Rensen, P.C.N. (author)
Summary: Background: The autonomic nervous system attenuates inflammation through activation of the α7 nicotinic acetylcholine receptor (α7nAChR), a pathway termed the cholinergic anti-inflammatory reflex. Interestingly, α7nAChR is expressed on immune cells and platelets, both of which play a crucial role in the development of atherosclerosis....
article 2015
document
van Dam, A.D. (author), Nahon, K.J. (author), Kooijman, S. (author), van den Berg, S.M. (author), Kanhai, A.A. (author), Kikuchi, T. (author), Heemskerk, M.M. (author), van Harmelen, V. (author), Lombès, M. (author), van den Hoek, A.M. (author), de Winther, M.P. (author), Lutgens, E. (author), Guigas, B. (author), Rensen, P.C. (author), Boon, M.R. (author)
Salsalate improves glucose intolerance and dyslipidemia in type 2 diabetes patients, but the mechanism is still unknown. The aim of the current study was to unravel the molecular mechanisms involved in these beneficial metabolic effects of salsalate by treating mice with salsalate during and after development of high-fat diet-induced obesity. We...
article 2015
document
Berbeé, J.F.P. (author), Boon, M.R. (author), Khedoe, P.P.S.J. (author), Bartelt, A. (author), Schlein, C. (author), Worthmann, A. (author), Kooijman, S. (author), Hoeke, G. (author), Mol, I.M. (author), John, C. (author), Jung, C. (author), Vazirpanah, N. (author), Brouwers, L.P.J. (author), Gordts, P.L.S.M. (author), Esko, J.D. (author), Hiemstra, P.S. (author), Havekes, L.M. (author), Scheja, L. (author), Heeren, J. (author), Rensen, P.C.N. (author)
Brown adipose tissue (BAT) combusts high amounts of fatty acids, thereby lowering plasma triglyceride levels and reducing obesity. However, the precise role of BAT in plasma cholesterol metabolism and atherosclerosis development remains unclear. Here we show that BAT activation by b3-adrenergic receptor stimulation protects from atherosclerosis...
article 2015
document
Geerling, J.J. (author), Boon, M.R. (author), van der Zon, G.C. (author), van den Berg, S.A.A. (author), van den Hoek, A.M. (author), Lombès, M. (author), Princen, H.M.G. (author), Havekes, L.M. (author), Rensen, P.C.N. (author), Guigas, B. (author)
Metformin is the first-line drug for the treatment of type 2 diabetes. Besides its well-characterized antihyperglycemic properties, metformin also lowers plasma VLDL triglyceride (TG). In this study, we investigated the underlying mechanisms in APOE*3-Leiden.CETP mice, a well-established model for human-like lipoprotein metabolism. We found that...
article 2014
document
Heemskerk, M.M. (author), van den Berg, S.A. (author), Pronk, A.C.M. (author), van Klinken, J.B. (author), Boon, M.R. (author), Havekes, L.M. (author), Rensen, P.C.N. (author), Willems van Dijk, K. (author), van Harmelen, V. (author)
The lipid-lowering effect of niacin has been attributed to the inhibition of cAMP production in adipocytes, thereby inhibiting intracellular lipolysis and release of nonesterified fatty acids (NEFA) to the circulation. However, long-term niacin treatment leads to a normalization of plasma NEFA levels and induces insulin resistance, for which the...
article 2014
document
Louwe, M.C. (author), Karper, J.C. (author), de Vries, M.R. (author), Nossent, A.Y. (author), Bastiaansen, A.J.N.M. (author), van der Hoorn, J.W.A. (author), Willems Van Dijk, K. (author), Rensen, P.C.N. (author), Steendijk, P. (author), Smit, J.W.A. (author), Quax, P.H.A. (author)
Background Toll-like receptor-4 (TLR4), a receptor of the innate immune system, is suggested to have detrimental effects on cardiac function after myocardial infarction (MI). RP105 (CD180) is a TLR4 homolog lacking the intracellular signaling domain that competitively inhibits TLR4-signaling. Thus, we hypothesized that RP105 deficiency, by...
article 2014
document
Bakker, L.E.H. (author), Boon, M.R. (author), van der Linden, R.A.D. (author), Arias-Bouda, L.P. (author), van Klinken, J.B. (author), Smit, F. (author), Verberne, H.J. (author), Jukema, J.W. (author), Tamsma, J.T. (author), Havekes, L.M. (author), van Marken Lichtenbelt, W.D. (author), Jazet, I.M. (author), Rensen, P.C.N. (author)
Background: Individuals of south Asian origin have a very high risk of developing type 2 diabetes compared with white Caucasians. We aimed to assess volume and activity of brown adipose tissue (BAT), which is thought to have a role in energy metabolism by combusting fatty acids and glucose to produce heat and might contribute to the difference...
article 2014
document
Louwe, M.C. (author), Karper, J.C. (author), de Vries, M.R. (author), Bastiaansen, A.J.N.M. (author), van der Hoorn, J.W.A. (author), Willems Van Dijk, K. (author), Rensen, P.C.N. (author), Steendijk, P. (author), Smit, J.W.A. (author), Quax, P.H.A. (author)
Purpose: Toll-like receptor-4 (TLR4), a receptor of the innate immune system, is suggested to have detrimental effects on cardiac function after myocardial infarction (MI). RP105 (CD180) is a TLR4 homolog lacking the intracellular signalling domain that competitively inhibits TLR4-signalling. Thus, we hypothesized that RP105 deficiency, by...
article 2014
document
Wang, Y. (author), Parlevliet, E.T. (author), Geerling, J.J. (author), van der Tuin, S.J.L. (author), Zhang, H. (author), Bieghs, V. (author), Jawad, A.H.M. (author), Shiri-Sverdlov, R. (author), Bot, I. (author), de Jager, S.C.A. (author), Havekes, L.M. (author), Romijn, J.A. (author), Willems Van Dijk, K. (author), Rensen, P.C.N. (author)
Background and Purpose The aetiology of inflammation in the liver and vessel wall, leading to non-alcoholic steatohepatitis (NASH) and atherosclerosis, respectively, shares common mechanisms including macrophage infiltration. To treat both disorders simultaneously, it is highly important to tackle the inflammatory status. Exendin-4, a glucagon...
article 2014
document
Boon, M.R. (author), Kooijman, S. (author), van Dam, A.D. (author), Pelgrom, L.R. (author), Berbée, J.F.P. (author), Visseren, C.A.R. (author), van Aggele, R.C. (author), van den Hoek, A.M. (author), Sips, H.C.M. (author), Lombès, M. (author), Havekes, L.M. (author), Tamsma, J.T. (author), Guigas, B. (author), Meijer, O.C. (author), Jukema, J.W. (author), Rensen, P.C.N. (author)
The endocannabinoid system is an important player in energy metabolism by regulating appetite, lipolysis, and energy expenditure. Chronic blockade of the cannabinoid 1 receptor (CB1R) leads to long-term maintenance of weight loss and reduction of dyslipidemia in experimental and human obesity. The molecular mechanism by which CB1R blockade...
article 2014
document
van den Berg, S.A.A. (author), Heemskerk, M.M. (author), Geerling, J.J. (author), van Klinken, J.B. (author), Schaap, F.G. (author), Bijland, S. (author), Berbée, J.F.P. (author), van Harmelen, V.J.A. (author), Pronk, A.C.M. (author), Schreurs, M. (author), Havekes, L.M. (author), Rensen, P.C.N. (author), van Dijk, K.W. (author)
Mutations in apolipoprotein A5 (APOA5) have been associated with hypertriglyceridemia in humans and mice. This has been attributed to a stimulating role for APOA5 in lipoprotein lipase-mediated triglyceride hydrolysis and hepatic clearance of lipoprotein remnant particles. However, because of the low APOA5 plasma abundance, we investigated an...
article 2013
document
Geerling, J.J. (author), Wang, Y. (author), Havekes, L.M. (author), Romijn, J.A. (author), Rensen, P.C.N. (author)
Objective: Central neuropeptide Y (NPY) administration stimulates food intake in rodents. In addition, acute modulation of central NPY signaling increases hepatic production of very low-density lipoprotein (VLDL)-triglyceride (TG) in rats. As hypertriglyceridemia is an important risk factor for atherosclerosis, for which well-established mouse...
article 2013
document
Berbée, J.F.P. (author), Wong, M.C. (author), Wang, Y. (author), van der Hoorn, J.W.A. (author), Khedoe, P.P.S.J. (author), van Klinken, J.B. (author), Mol, I.M. (author), Hiemstra, P.S. (author), Tsikas, D. (author), Romijn, J.A. (author), Havekes, L.M. (author), Princen, H.M.G. (author), Rensen, P.C.N. (author)
Resveratrol is a major constituent of traditional Asian medicinal herbs and red wine and is suggested to be a potential antiatherosclerotic drug due to its proposed hypolipidemic, anti-inflammatory and antioxidative properties. The aim of this study was to evaluate whether resveratrol protects against atherosclerosis development in APOE*. 3...
article 2013
document
van Diepen, J.A. (author), Berbée, J.F.P. (author), Havekes, L.M. (author), Rensen, P.C.N. (author)
Dyslipidemia and inflammation are well known causal risk factors the development of atherosclerosis. The interplay between lipid metabolism and inflammation at multiple levels in metabolic active tissues may exacerbate the development of atherosclerosis, and will be discussed in this review. Cholesterol, fatty acids and modified lipids can...
article 2013
document
Auvinen, H.E. (author), Wang, Y. (author), Princen, H. (author), Romijn, J.A. (author), Havekes, L.M. (author), Smit, J.W.A. (author), Meijer, O.C. (author), Biermasz, N.R. (author), Rensen, P.C.N. (author), Pereira, A.M. (author)
Introduction: The role of glucocorticoids in atherosclerosis development is not clearly established. Human studies show a clear association between glucocorticoid excess and cardiovascular disease, whereas most animal models indicate an inhibitory effect of glucocorticoids on atherosclerosis development. These animal models, however, neither...
article 2013
document
Kühnast, S. (author), Louwe, M.C. (author), Heemskerk, M.M. (author), Pieterman, E.J. (author), van Klinken, J.B. (author), van den Berg, S.A.A. (author), Smit, J.W.A. (author), Havekes, L.M. (author), Rensen, P.C.N. (author), van der Hoorn, J.W.A. (author), Princen, H.M.G. (author), Jukema, J.W. (author)
Objective:Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely increases HDL-cholesterol. Despite evidence for an atheroprotective effect of niacin from previous small clinical studies, the large outcome trials, AIM-HIGH and HPS2-THRIVE did not reveal additional beneficial effects of niacin (alone or in combination...
article 2013
document
Auvinen, H.E. (author), Coomans, C.P. (author), Boon, M.R. (author), Romijn, J.A. (author), Biermasz, N.R. (author), Meijer, O.C. (author), Havekes, L.M. (author), Smit, J.W.A. (author), Rensen, P.C.N. (author), Pereira, A.M. (author)
article 2013
document
Li, Z. (author), Wang, Y. (author), van der Sluis, R.J. (author), van der Hoorn, J.W.A. (author), Princen, H.M.G. (author), van Eck, M. (author), van Berkel, T.J.C. (author), Rensen, P.C.N. (author), Hoekstra, M. (author)
The anti-dyslipidemic drug niacin has recently been shown to reduce the hepatic expression and plasma levels of CETP. Since liver macrophages contribute to hepatic CETP expression, we investigated the role of macrophages in the CETP-lowering effect of niacin in mice. In vitro studies showed that niacin does not directly attenuate CETP expression...
article 2012
Searched for:
(1 - 20 of 39)

Pages